文献速递肝病胰腺与胆道疾病

评估原发性硬化性胆管炎患者肝功能的影像生物标志物

An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-07-11

研究纳入111例确诊原发性硬化性胆管炎(PSC)患者,在注射肝细胞特异性对比剂钆塞酸二钠前后行肝胆期磁共振成像(MRI),测量各肝段信号强度并计算平均相对强化值。相对强化值与碱性磷酸酶、胆红素、白蛋白、国际标准化比值及MELD、Mayo风险、Amsterdam-Oxford评分相关,并识别临床终点(73.9%灵敏度、92.9%特异度)。作者认为需长期多中心研究进一步评估该标志物。

要点

  • 注射钆塞酸二钠后20分钟相对强化值与碱性磷酸酶(r=-0.636)、胆红素(r=-0.646)呈负相关。
  • 相对强化值与MELD评分(r=-0.587)、Mayo风险评分(r=-0.535)、Amsterdam-Oxford模型评分(r=-0.595)相关(P<.0001)。
  • 相对强化值截断值0.65识别临床终点的灵敏度73.9%、特异度92.9%,曲线下面积0.901。

核心结论

  • 在111例PSC患者分析中,使用肝细胞特异性对比剂的MRI测量相对强化值,以73.9%灵敏度、92.9%特异度识别具有临床结局的患者。
  • 作者认为需长期、多中心研究进一步评估该PSC进展标志物。

研究设计与样本

  • 收集2012年3月至2016年3月间111例确诊PSC患者(男83例、女28例;中位年龄44岁)的数据。
  • 患者在注射肝细胞特异性对比剂钆塞酸二钠前及注射后(肝胆期)行MRI评估。
  • 测量每个肝段信号强度,计算平均相对强化值,并与肝功能检查、预后评分系统、内镜逆行胰胆管造影异常及临床终点进行相关性分析。
  • 主要目的是将相对强化值与肝功能及患者结局相关联。

主要发现

  • 多数患者为中度疾病阶段且风险水平居中(中位MELD评分8,中位Mayo评分0.27)。
  • 21例患者达到临床终点:6例发生胆管癌、8例接受肝移植、7例死亡。
  • 注射对比剂后20分钟相对强化值与碱性磷酸酶(r=-0.636)、胆红素(r=-0.646)、白蛋白(r=0.538)、国际标准化比值(r=0.456)相关(P<.0001)。
  • 相对强化值与MELD评分(r=-0.587)、Mayo风险评分(r=-0.535)、Amsterdam-Oxford模型评分(r=-0.595)相关(P<.0001)。
  • 相对强化值与所有临床终点相关(均P<.05)。

关键数值与推荐

  • 相对强化值截断值0.65识别临床终点的灵敏度73.9%、特异度92.9%(受试者工作特征曲线下面积0.901;似然比10.34;P<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者结论指出需长期、多中心研究进一步评估该PSC进展标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to evaluate the potential of hepatobiliary phase magnetic resonance imaging (MRI) as parameter for assessment of hepatocellular function in patients with primary sclerosing cholangitis (PSC). METHODS: We collected data from 111 patients (83 male, 28 female; median, 44 years old), from March 2012 through March 2016, with a confirmed diagnosis of PSC who underwent MRI evaluation before and after injection (hepatobiliary phase) of a hepatocyte-specific contrast agent (gadoxetate disodium). Signal intensities were measured in each liver segment. Mean relative enhancement values were calculated and correlated with findings from liver functions tests, prognostic scoring systems (model for end-stage liver disease [MELD] score; Mayo risk score; Amsterdam-Oxford-PSC score), abnormalities detected by endoscopic retrograde cholangiopancreatography (using the Amsterdam cholangiographic classification system), and clinical endpoints (liver transplantation, cholangiocarcinoma, liver-related death). Our primary aim was to associate relative enhancement values with liver function and patient outcomes. RESULTS: Most patients had moderate-stage disease and had intermediate levels of risk (median MELD score, 8 and median Mayo score, 0.27). Clinical endpoints were reached by 21 patients (6 developed cholangiocarcinoma, 8 underwent liver transplantation, and 7 patients died). The highest levels of correlations were observed for relative enhancement 20 min after contrast injection and level of alkaline phosphatase (r = -0.636), bilirubin (r = -0.646), albumin (r = 0.538); as well as international normalized ratio (r = 0.456); MELD score (r = -0.587); Mayo risk score (r = -0.535), and Amsterdam-Oxford model score (r = -0.595) (P < .0001). Relative enhancement correlated with all clinical endpoints (all P < .05). A cutoff relative enhancement value of 0.65 identified patients with a clinical endpoint with 73.9% sensitivity 92.9% specificity (area under the receiver operating characteristic curve, 0.901; likelihood ratio, 10.34; P < .0001). CONCLUSIONS: In an analysis of 111 patients with PSC, we found MRI-measured relative enhancement, using a hepatocyte-specific contrast agent, to identify patients with clinical outcomes with 73.9% sensitivity 92.9% specificity. Long-term, multicenter studies are needed to further evaluate this marker of PSC progression.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Schulze J, Lenzen H, Hinrichs JB, et al. An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2018. PMID: 29775791. doi:10.1016/j.cgh.2018.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。